NCT02506751View on ClinicalTrials.gov

Open-label Study of Liothyronine in MS

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

September 18, 2017

Study Completion Date

September 18, 2017

Conditions
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Secondary ProgressiveMultiple Sclerosis, Primary Progressive
Interventions
DRUG

liothyronine

All eligible subjects will be treated with the study drug as per the standardized dose-escalation protocol. Subjects will be required to report to the study site every six weeks for the duration of the study in order to receive their study drug and to monitor drug safety and tolerability.

Trial Locations (1)

21287

The Johns Hopkins Hospital, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER

NCT02506751 - Open-label Study of Liothyronine in MS | Biotech Hunter | Biotech Hunter